In May 2001, the world's first targeted drug, Gleevec, was approved for marketing, marking the treatment of chronic myelogenous leukemia (hereafter referred to as CML) using tyrosine kinase inhibitors (hereafter referred to as TKIs). referred to in) is entering the era of. The scientific name of Gleevec is imatinib mesylate, which is a first-generation TKI.
Gleevec's patent for treating leukemia expired in April 2013. Three domestic generic drugs have received production approval and will soon be ready for mass production.
These drugs have anti-tumor cell proliferation and cytotoxic effects. After use, they can temporarily control the increase in white blood cells and shrink the spleen, but they cannot delay the progression of the disease.
For more info- https://www.medixocentre.com/gleevec-imatinib-cost
Gleevec's patent for treating leukemia expired in April 2013. Three domestic generic drugs have received production approval and will soon be ready for mass production.
These drugs have anti-tumor cell proliferation and cytotoxic effects. After use, they can temporarily control the increase in white blood cells and shrink the spleen, but they cannot delay the progression of the disease.
For more info- https://www.medixocentre.com/gleevec-imatinib-cost
Discuţie
- 0 cometariu
Hopa! Nu există comentarii în acest moment.
Hopa! Vă rugăm să vă logați sau să vă înregistrați pentru a adăuga comentarii
Medixo Centre 2018
Nepal / Bagmati / Kathmandu
नेरू 1,500.00
-
Evitați înșelătoriile acționând la nivel local sau plătiți cu PayPal
-
Nu plătiți niciodată cu Western Union, Moneygram sau alte servicii de plată anonime
-
Nu cumpărați sau vindeți în afara țării dvs. Nu acceptați cecuri de casier din afara țării dvs.
-
Acest site nu este niciodată implicat în nicio tranzacție și nu se ocupă de plăți, transport, tranzacții de garanție, oferă servicii de escrow sau oferă 'protecție pentru cumpărători'
Find US on Facebook
